Trial Profile
RE-SPECT CVT: a Randomised, Open-label, Exploratory Trial With Blinded Endpoint Adjudication (PROBE), Comparing Efficacy and Safety of Oral Dabigatran Etexilate Versus Oral Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis Over a 24-week Period
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Apr 2022
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary) ; Warfarin
- Indications Venous thrombosis
- Focus Therapeutic Use
- Acronyms RE-SPECT CVT
- Sponsors Boehringer Ingelheim
- 25 Sep 2020 Results published in the Stroke
- 04 Sep 2019 Safety and efficacy results presented in the Boehringer Ingelheim media release.
- 03 Sep 2019 Results evaluating the efficacy and safety of dabigartan compared with dose-adjusted warfarin in the prevention of recurrent venous thrombotic events and Cerebral venous thrombosis published in the JAMA Neurology